Optune Lua was FDA approved under the HDE pathway1,2

Optune Lua for MPM is classified as a Humanitarian Use Device (HUD), approved under the Humanitarian Device Exemption (HDE) pathway

An HUD is a medical device intended to benefit patients with a disease or condition that affects fewer than 8,000 individuals in the United States per year.3

The HDE pathway was implemented by the FDA to encourage:

Innovation in rare diseases

Companies to innovate in rare diseases with underserved patient populations

Once approved by the FDA through the HDE pathway, use of the HUD in a facility is overseen by an appropriate Local Committee (LC) or the Institutional Review Board (IRB)

See how Optune Lua works

An HDE may be granted if3:

Probable benefit outweighs risk

The device will not expose patients to an unreasonable or significant risk of illness or injury, and the probable benefit to health from use of the device outweighs the risk of injury or illness from its use while taking into account the probable risks and benefits of currently available devices or alternative forms of treatment

Device not available without the HDE

The device would not be available to a person with the disease or condition in question without the HDE

Condition affects not more than 8,000 in the United States

The device is designed to treat or diagnose a disease or condition that affects not more than 8,000 individuals
in the United States per year

Optune Lua is the first FDA-approved MPM treatment in over 15 years4-6

See overall survival results

MPM, malignant pleural mesothelioma.

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702-1709. 3. US FDA. Humanitarian Device Exemption (HDE) Program: Draft Guidance for Industry and Food and Drug Administration Staff. September 6, 2019. https://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/UCM389275.pdf. Accessed January 3, 2020. 4. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 5. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644.

Next: Mesothelioma Treatment Overview | Optune Lua™
Indications For Use
jump to isi

The Optune Lua System is indicated for the treatment of adult patients with unresect…

Leaving OptuneLua.com

Novocure® does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.